Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)

A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.

Also Known As:

Ki 1 Lymphoma; Lymphoma, Large-Cell, Anaplastic; CD30+ Anaplastic Large-Cell Lymphoma; Ki-1 Lymphoma; Systemic Anaplastic Large-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Anaplastic Large-Cell Lymphomas; CD30 Positive Anaplastic Large Cell Lymphoma; CD30+ Anaplastic Large Cell Lymphoma; Ki-1 Lymphomas; Large-Cell Lymphoma, Anaplastic; Large-Cell Lymphomas, Anaplastic; Lymphoma, Anaplastic Large-Cell; Lymphoma, Ki-1; Lymphomas, Anaplastic Large-Cell; Lymphomas, Ki-1; Systemic Anaplastic Large Cell Lymphoma; CD30-Positive Anaplastic Large-Cell Lymphoma; Lymphoma, Large-Cell, Ki-1

Networked: 2329 relevant articles (79 outcomes, 163 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hodgkin Disease (Hodgkin's Disease)
2.	T-Cell Lymphoma (Lymphoma, T Cell)
3.	Neoplasms (Cancer)
4.	Lymphoma (Lymphomas)
5.	Non-Hodgkin Lymphoma (Lymphosarcoma)

Experts

1.	Medeiros, L Jeffrey: 63 articles (01/2022 - 05/2002)
2.	Clemens, Mark W: 58 articles (10/2022 - 08/2014)
3.	Miranda, Roberto N: 46 articles (10/2022 - 04/2012)
4.	Inghirami, Giorgio: 39 articles (01/2021 - 02/2002)
5.	Turner, Suzanne D: 37 articles (10/2022 - 10/2003)
6.	Lai, Raymond: 36 articles (12/2021 - 09/2002)
7.	Rassidakis, George Z: 30 articles (06/2022 - 09/2002)
8.	Kadin, Marshall E: 29 articles (12/2022 - 07/2003)
9.	Lamant, Laurence: 28 articles (01/2021 - 08/2003)
10.	Deva, Anand K: 23 articles (06/2022 - 02/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Anaplastic Large-Cell Lymphoma:

1.	Brentuximab VedotinIBA 08/15/2013 - "Brentuximab vedotin is an effective treatment of relapsed CD30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas. " 01/01/2021 - "Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). " 01/01/2018 - "Relapsed anaplastic large-cell lymphoma exhibits improved prognosis with the approved anti-CD30 drug conjugate brentuximab vedotin. " 12/21/2017 - "This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). " 01/01/2022 - "Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data."
2.	Anaplastic Lymphoma KinaseIBA 01/01/2012 - "Apart from anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, that have a good outcome, other nodal and extranodal forms have a 5-year overall survival of about 30%. " 01/01/2015 - "Our current understanding of oncogenic Anaplastic Lymphoma Kinase (ALK)-induced lymphomagenesis has relied for over 20 years on multiple and complementary studies performed on various experimental models, encompassing ALK oncogene expressing cells, their grafts into immune-compromised mice, the generation of genetically engineered mouse models (GEMMs) and, when available, the use of patient samples from Anaplastic Large Cell Lymphoma (ALCL) tumour banks. " 02/01/2013 - " Patients with anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+-ALCL) were excluded from this study. " 02/01/2013 - "The aim of this study was to investigate the pathological features of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) in children and to establish the effectiveness of screening and diagnosing ALCL with multiparameter flow cytometry immunophenotyping (FCI) of lymphoid tissue samples. " 07/01/2009 - "Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma has a significantly better prognosis than anaplastic lymphoma kinase-negative anaplastic large cell lymphoma and molecular studies have illustrated that each entity has a distinct molecular profile. "
3.	CrizotinibIBA 01/01/2020 - "Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report." 01/01/2017 - "To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). " 01/01/2023 - "Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial." 05/01/2013 - "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study." 01/01/2023 - "[Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics]."
4.	Proteins (Proteins, Gene)FDA Link 04/01/2008 - "To compare the efficacy of nuclear microarray combined with fluorescence in situ hybridization (FISH) and immunohistochemistry in detecting ALK gene translocation and ALK fusion protein in anaplastic large cell lymphoma (ALCL). " 06/14/2022 - "ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment." 06/08/2021 - "Objective: To investigate the genetic abnormality and protein expression of C-MYC and PD-L1 in the patients with ALK-negative anaplastic large cell lymphoma (ALK－ALCL), and to explore their roles in the pathogenesis of ALK－ALCL and their relationship with clinicopathological characteristics. " 06/08/2021 - "[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma]." 01/01/2021 - "The lytic lesion biopsy revealed anaplastic large cell lymphoma with ALK protein expression. "
5.	Phosphotransferases (Kinase)IBA 12/01/2022 - "Among 1553 PTCL patients, 131 (8.4% of the total cohort) were confirmed to have anaplastic large cell lymphoma - kinase positive (ALCL, ALK+). " 05/01/2019 - "Histology revealed an extensively decidualized spindle cell process, positive for anaplastic large cell lymphoma kinase (ALK) through immunohistochemistry and fluorescent in situ hybridization (FISH). " 04/26/2016 - "Here we assess the impact of several kinase-domain mutations that arose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL) cell lines. " 01/01/2016 - "But anaplastic large cell lymphoma kinase (ALK)+ ALCL with soft tissue involvement is very rare. " 04/13/2015 - "Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma."
6.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/01/2003 - "A 39-year-old male underwent a nonmyeloablative stem cell transplant (NMAPBPCT) from his HLA-matched sister for recurrent anaplastic large cell lymphoma in CR-2, receiving fludarabine, cyclophosphamide, and rabbit antithymocyte globulin for the preparative therapy. " 01/01/2022 - "The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. " 10/11/2022 - "Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. " 05/01/2012 - "Anaplastic large-cell lymphoma is the only subgroup to have a good response to a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimen. " 11/01/1993 - "The index patient and second patient were diagnosed as having Ki-1-positive anaplastic large-cell lymphoma by immunophenotyping and underwent cyclophosphamide, doxorubicin, prednisone, and vincristine (CHOP) chemotherapy with complete remission. "
7.	Vinblastine (Vinblastine Sulfate)FDA Link 10/20/2009 - "To evaluate the efficacy of vinblastine for relapsed/refractory anaplastic large-cell lymphoma (ALCL). " 12/01/2014 - "Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group." 09/01/2010 - "Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial." 08/01/2015 - "Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen." 02/01/2011 - "Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective."
8.	liposomal doxorubicin (Doxil)FDA Link 06/01/2003 - "Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission." 11/01/2013 - "Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma." 11/01/2013 - "In this study, we compared the therapeutic efficacy of Doxil(®) (commercial doxorubicin-loaded liposomes) and that of Doxil(®) conjugated with anti-CD30 antibodies (CD30-targeted Doxil(®)) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression. " 11/01/2015 - "A phase II study was performed to evaluate the efficacy of hyper-fractionated cyclophosphamide, vincristine, pegylated liposomal doxorubicin and dexamethasone alternating with methotrexate/cytarabine (HCVIDD/MA) in patients with newly diagnosed peripheral T-cell lymphoma (PTCL), excluding ALK-positive anaplastic large cell lymphoma. "
9.	Vincristine (Oncovin)FDA LinkGeneric 10/11/2022 - "Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. " 05/01/2012 - "Anaplastic large-cell lymphoma is the only subgroup to have a good response to a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimen. " 11/01/1993 - "The index patient and second patient were diagnosed as having Ki-1-positive anaplastic large-cell lymphoma by immunophenotyping and underwent cyclophosphamide, doxorubicin, prednisone, and vincristine (CHOP) chemotherapy with complete remission. " 12/01/2023 - "CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)- based chemotherapy continues to be the 'standard' treatment, with the addition of brentuximab vedotin (BV) in the combination CHP (cyclosphosphamide, doxorubicin, prednisone)-BV representing a new treatment paradigm in CD30+ PTCL although its benefit is less certain in the non-anaplastic large cell lymphoma subtypes. " 01/31/2021 - "The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. "
10.	Doxorubicin (Adriamycin)FDA LinkGeneric 03/01/2013 - "The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large-cell lymphoma (ALCL) treated with doxorubicin-based chemotherapy and radiotherapy. " 03/01/2013 - "Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma." 09/01/2002 - "From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). " 06/10/2019 - "CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells." 01/01/2018 - "Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 12/30/2002 - "Patients with anaplastic large cell lymphoma (ALCL) who were treated with similar alternating short courses of multi-agent chemotherapy had a less good outcome (n = 20; relapse, n = 6, progression, n = 3). " 01/01/2022 - "BV may be a cost-effective treatment vs. chemotherapy in treating relapsed or refractory systemic anaplastic large-cell lymphoma in China." 11/15/1998 - "The purpose of this study was (1) to investigate the efficacy of chemotherapy regimens designed by the French Society of Pediatric Oncology for childhood anaplastic large-cell lymphoma (ALCL) and (2) to identify prognostic factors in these children. " 09/01/2009 - "We describe the unusual case of a 14-year-old adolescent with a locally disseminated ovarian anaplastic large-cell lymphoma, treated with surgery followed by chemotherapy, and who remains disease free at 2 years after diagnosis." 10/01/2002 - "Here we describe a unique case of primary neutrophil-rich CD30-positive anaplastic large cell lymphoma (ALCL) of the stomach that was treated and cured by combined chemotherapy. "
2.	Therapeutics 05/01/2016 - "Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy." 05/01/2013 - "In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. " 08/01/2011 - "Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study." 07/01/2011 - "Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial." 03/13/2009 - "With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma. "
3.	Stem Cell Transplantation 01/01/2021 - "[Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation]." 02/01/2015 - "Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan." 06/01/2000 - "Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial." 01/01/2020 - "Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. " 02/01/2015 - "To evaluate haematopoietic stem cell transplantation (HSCT) in children and adolescents, we reviewed the records of 47 patients who were ≤18 years, had relapsed or refractory anaplastic large cell lymphoma, and received HSCT between 1990 and 2010. "
4.	Hematopoietic Stem Cell Transplantation 09/28/2022 - "Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation." 06/01/2015 - "Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC." 02/14/2020 - "Objective: To explore the efficacy and prognostic factors of hematopoietic stem cell transplantation (HSCT) for the treatment of patients with anaplastic large cell lymphoma (ALCL) . " 02/14/2020 - "[Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation]." 02/01/2020 - "A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children."
5.	Breast Implants (Breast Implant) 01/01/2021 - "The United States Food and Drug Administration (FDA) recently recognized the necessity for improved patient education and public awareness of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). " 01/01/2023 - "A quantitative analysis was performed by two independent researchers on cases extracted from 52 primary studies (case report, case series, and systematic review) published until April 2022 and searched in PubMed, Scopus, and Google-Scholar databases using "Breast-Implant" AND/OR "Associated" AND/OR "Anaplastic-Large-Cell-Lymphoma". " 10/01/2021 - "This study aimed to illustrate the epidemiological situation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by focusing on the changes published after 2019 and particularly the new approaches of cosmetic and reconstructive breast surgery. " 05/01/2021 - "The aim of this study was to specifically look for social media posts addressing breast augmentation, breast implants, and breast implant associated anaplastic large cell lymphoma (BIA-ALCL).The aims of this study were to examine social media posting regarding BIA-ALCL and to analyze the ways general public receive information regarding this disease. " 05/01/2021 - "In the past few years, the number of women with breast implants diagnosed with anaplastic large cell lymphoma (ALCL) has increased, and several studies have suggested a direct association between breast implants and an increased risk of this disease. "